AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

38. (Currently Amended) A method of raising an immune response in an individual against an antigen or antigenic composition, comprising administering intranasally to said individual a vaccine composition comprising an adjuvant composition, [[and]] an antigen or antigenic composition, and at least one immunostimulant; wherein the adjuvant composition is selected from the group consisting of: a non-vesicular aqueous solution and a suspension of a surfactant of formula (I): $HO(CH_2CH_2O)_n$-A-R wherein, *n* is 1-50, *A* is a bond or -C(O)-, *R* is C_{1-50} alkyl or Phenyl C_{1-50} alkyl.

39. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the surfactant of formula (I) is haemolytic.

40. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the adjuvant composition is characterized in that the surfactant of formula (I) is not in the form of a vesicle and also in that the degree of haemolytic activity is in the range of 0.05-0.0001% as measured in the Guinea Pig blood haemolysis assay.

41. (Previously Presented) A method of raising an immune response as claimed in Claim 39, wherein the surfactant of formula (I) has a haemolytic activity within a ten fold difference to that of polyoxyethylene-9 lauryl ether or polyoxyethylene-8 stearyl ether, as measured in the Guinea Pig blood haemolysis assay.

42. (Previously Presented) A method of raising an immune response as claimed in any one of the Claims 38 and 39-41, using an adjuvant that is a surfactant of formula (I), wherein *n* is 4 to 24.

43. (Currently Amended) A method of raising an immune response as claimed in Claim 38, wherein the adjuvant ~~that~~ is a surfactant of formula (I), wherein R is C_{8-20} alkyl or Phenyl C_{8-20} alkyl.

44. (Currently Amended) A method of raising an immune response as claimed in Claim 39, wherein the adjuvant ~~that~~ is a surfactant of formula (I), wherein R is C_{8-20} alkyl or Phenyl C_{8-20} alkyl.

45. (Currently Amended) A method of raising an immune response as claimed in Claim 40, wherein the adjuvant ~~that~~ is a surfactant of formula (I), wherein R is C_{8-20} alkyl or Phenyl C_{8-20} alkyl.

46. (Currently Amended) A method of raising an immune response as claimed in Claim 41, wherein the adjuvant ~~that~~ is a surfactant of formula (I), wherein R is C_{8-20} alkyl or Phenyl C_{8-20} alkyl.

47. (Previously Presented) A method of raising an immune response as claimed in Claim 42, wherein the adjuvant ~~that~~ is a surfactant of formula (I), wherein R is C_{8-20} alkyl or Phenyl C_{8-20} alkyl.

48. (Previously Presented) A method of raising an immune response as claimed in Claim 38 wherein n is 9, A is a bond or -C(O)-, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl and is characterized in that the surfactant of formula (I) is not in the form of a vesicle.

49. (Previously Presented) A method of raising an immune response as claimed in Claims 43 or 44, wherein R is C_{12} alkyl.

50. (Currently Amended) A method of raising an immune response as claimed in Claim[[s]] 43, wherein R is C_{12} alkyl.

51. (Previously Presented) A method of raising an immune response as claimed in Claim 38 wherein n is 8, A is a bond or -C(O)-, R is C_{1-50} alkyl or Phenyl C_{1-50} alkyl and is characterized in that the surfactant of formula (I) is not in the form of a vesicle.

52. (Previously Presented) A method of raising an immune response as claimed in Claim 46, wherein R is C_{18} alkyl.

53. (Previously Presented) A method of raising an immune response as claimed in Claim 38, comprising a surfactant of formula (I), wherein A is a bond, thereby forming an ether.

54. (Previously Presented) A method of raising an immune response as claimed in Claim 38 comprising a surfactant of formula (I), wherein A is –C(O)-, thereby forming an ester.

55. (Currently Amended) A method of raising an immune response as claimed in Claim 38, wherein the polyoxyethylene ether or ester of formula (I) is selected from a group consisting of: polyoxyethylene 9-lauryl ether, polyoxyethylene-9-lauryl ester, polyoxyethylene-9- stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether and polyoxyethylene-23-lauryl ether.

56. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the concentration of the surfactant is in the range of 0.1-10%.

57. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the concentration of the surfactant is in the range of 0.25-1%.

58. (Cancelled)

59. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the antigen or antigen composition is derived from the group consisting of: Human Immunodeficiency Virus, Varicella Zoster virus, Herpes Simplex Virus type 1,

Herpes Simplex virus type 2, Human cytomegalovirus, Dengue virus, Hepatitis A, B, C or E, Respiratory syncytial virus, human papilloma virus, Influenza virus, Hib, Meningitis virus, Salmonella, Neisseria, Borrelia, Chalamydia, Bordetella, Streptococcus, Mycoplasma, Mycobacteria, Haemophilus, Plasmodium or Toxoplasma, IgE peptides such as the stanworth decapeptide and Tumor associated antigen (TMA) such as MAGE, BAGE, GAGE, MUC-1, Her-2 neu, LnRH, CEA, PSA, KSA, or PRAME.

60. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the vaccine comprises polyoxyethylene-9 lauryl ether and an influenza virus antigen.

61. (Previously Presented) A method of raising an immune response as claimed in Claim 38, wherein the vaccine is in the form of an aerosol or a spray.

62. (Previously Presented) A spray device, more particularly a bi-dose spray device, filled with a vaccine suitable for use in the method of raising an immune response as claimed in Claim 38.

63. (Previously Presented) A method of treatment, using the method of Claim 38, of a mammal suffering from or susceptible to a group of diseases consisting of: a pathogenic infection, cancer and allergy, comprising the intranasal administration of a safe and effective amount of a vaccine composition according to Claims 58-61.

64. (Previously Presented) A process for making a vaccine composition for the use in the method of Claim 38, comprising admixing (a) an adjuvant composition comprising a surfactant of formula (I), (b) a pharmaceutically acceptable excipient, and (c) an antigen or antigenic composition.

65. (New) The method of claims 38-41, 43-46, 48, 50-57, and 59-64 wherein said immunostimulant is selected from the group consisting of: LT, CT, 3D-MPL, CpG and QS21.